Clinical Trial Update: Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and tolerability of a single administration of FOV2302 (ecallantide) in macular edema associated with central retinal vein…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• FOV2302 (ecallantide)

Snippet

Sponsor: Fovea Pharmaceuticals SA | Conditions: Macular Edema, Central Retinal Vein Occlusion | Phase 1 | Status: TERMINATED